Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvo+™ (atorvastatin + CBD) in healthy adults
NCT06615284Phase 1Completed
- Sponsor
- Indication Bioscience
- Start
- Jan 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of cannabidiol in coronary heart disease (CHD) and dyslipidemia (3 arms), sponsored by Indication Bioscience. Primary endpoints: Adverse Events at 42 days, Serious Adverse Events at 42 days and 2 more. Started Jan 2025; status: completed.
02
Drugs
cannabidiol
03
Conditions
coronary heart disease (CHD)dyslipidemia
Beyond the preview
Go deeper on NCT06615284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06615284.